[go: up one dir, main page]

MX2019007540A - Derivados de pirazol como inhibidores de malt1. - Google Patents

Derivados de pirazol como inhibidores de malt1.

Info

Publication number
MX2019007540A
MX2019007540A MX2019007540A MX2019007540A MX2019007540A MX 2019007540 A MX2019007540 A MX 2019007540A MX 2019007540 A MX2019007540 A MX 2019007540A MX 2019007540 A MX2019007540 A MX 2019007540A MX 2019007540 A MX2019007540 A MX 2019007540A
Authority
MX
Mexico
Prior art keywords
pyrazole derivatives
malt1 inhibitors
malt1
inhibitors
compounds
Prior art date
Application number
MX2019007540A
Other languages
English (en)
Other versions
MX392673B (es
Inventor
Shen Fang
Kent Barbay Joseph
Jean- Claude Berthelot Didier
Wu Tongfei
patrick edwards James
D Kreutter Kevin
Lu Tianbao
Douglas Allison Brett
J Connolly Peter
David Cummings Maxwell
Diels Gaston
Philippar Ulrike
Wilhelmus John Fitzgerald Thuring Johannes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2019007540A publication Critical patent/MX2019007540A/es
Publication of MX392673B publication Critical patent/MX392673B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar enfermedades, síndromes, condiciones o trastornos que son afectados por la modulación de MALT1. Tales compuestos se representan mediante la Fórmula (I): ( Ver Fórmula I), en donde R1, R2, R3, R4, R5, R6, R5, G1, y G2 se definen en la presente descripción.
MX2019007540A 2016-12-21 2017-12-20 Derivados de pirazol como inhibidores de malt1 MX392673B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437384P 2016-12-21 2016-12-21
PCT/US2017/067516 WO2018119036A1 (en) 2016-12-21 2017-12-20 Pyrazole derivatives as malt1 inhibitors

Publications (2)

Publication Number Publication Date
MX2019007540A true MX2019007540A (es) 2019-10-24
MX392673B MX392673B (es) 2025-03-24

Family

ID=61628454

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019007540A MX392673B (es) 2016-12-21 2017-12-20 Derivados de pirazol como inhibidores de malt1
MX2022005827A MX2022005827A (es) 2016-12-21 2019-06-21 Derivados de pirazol como inhibidores de malt1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005827A MX2022005827A (es) 2016-12-21 2019-06-21 Derivados de pirazol como inhibidores de malt1.

Country Status (23)

Country Link
US (2) US10954214B2 (es)
EP (1) EP3558969B1 (es)
JP (1) JP7138641B2 (es)
KR (1) KR102583317B1 (es)
CN (1) CN110214136A (es)
AR (1) AR110421A1 (es)
AU (2) AU2017382185C1 (es)
BR (1) BR112019012355A2 (es)
CA (1) CA3048027A1 (es)
CL (1) CL2019001709A1 (es)
CO (1) CO2019006622A2 (es)
EA (1) EA201991503A1 (es)
ES (1) ES2992411T3 (es)
IL (1) IL267343B2 (es)
MA (1) MA47125A (es)
MX (2) MX392673B (es)
PE (1) PE20191755A1 (es)
PH (1) PH12019501212A1 (es)
TN (1) TN2019000192A1 (es)
TW (1) TWI795381B (es)
UA (1) UA127920C2 (es)
UY (1) UY37537A (es)
WO (1) WO2018119036A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EP3828171A1 (en) 2015-12-22 2021-06-02 Incyte Corporation Heterocyclic compounds as immunomodulators
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
AU2017281285C1 (en) 2016-06-20 2022-05-12 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
PL3697785T3 (pl) 2017-10-18 2023-08-07 Jubilant Epipad LLC Związki imidazopirydynowe jako inhibitory pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
DK3704120T3 (da) 2017-11-24 2024-05-21 Jubilant Episcribe Llc Heterocykliske forbindelser som prmt5-inhibitorer
WO2019133809A1 (en) 2017-12-28 2019-07-04 The General Hospital Corporation Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
KR20250067967A (ko) 2018-03-30 2025-05-15 인사이트 코포레이션 면역조절제로서 복소환형 화합물
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
US10888550B2 (en) * 2018-06-18 2021-01-12 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
US11040031B2 (en) * 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
TW202045008A (zh) * 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
CA3129623A1 (en) * 2019-02-22 2020-08-27 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
BR112021016411A2 (pt) 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Formulações farmacêuticas
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
TWI879811B (zh) 2019-09-30 2025-04-11 美商英塞特公司 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
TW202132288A (zh) * 2019-10-24 2021-09-01 日商小野藥品工業股份有限公司 Ｔｒｅｋ（ｔｗｉｋ相關的ｋ＋通道）通道功能的調節劑
US20220411429A1 (en) * 2019-10-30 2022-12-29 Biogen Ma Inc. Condensed pyridazine or pyrimidine as btk inhibitors
PH12022551136A1 (en) 2019-11-11 2023-10-09 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2021099612A1 (en) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors
CA3162140A1 (en) * 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assay
WO2021138298A1 (en) * 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
CN115884773A (zh) 2020-08-21 2023-03-31 詹森药业有限公司 药物制剂
AU2021328320A1 (en) * 2020-08-21 2023-05-04 Janssen Pharmaceutica Nv Amorphous form of a malt1 inhibitor and formulations thereof
EP4228647A4 (en) * 2020-10-16 2024-09-11 Rarefied Biosciences, Inc. MALT1 MODULATORS AND THEIR USES
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN116670114A (zh) 2020-11-06 2023-08-29 因赛特公司 用于制备pd-1/pd-l1抑制剂以及其盐和结晶形式的方法
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
US20230414629A1 (en) * 2020-11-12 2023-12-28 Monopteros Therapeutics, Inc. Materials and methods of treating cancer
GB202018412D0 (en) * 2020-11-23 2021-01-06 Exscientia Ltd Malt-1 modulators ii
WO2022167962A1 (en) * 2021-02-04 2022-08-11 Aurigene Discovery Technologies Limited Substituted pyrazolyl compounds as malt-1 inhibitors
KR20230154232A (ko) * 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 Malt1 억제제 및 btk 억제제를 사용하는 병용 치료
WO2022185097A1 (en) 2021-03-03 2022-09-09 Janssen Pharmaceutica Nv Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)
CN117120427A (zh) * 2021-06-18 2023-11-24 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
WO2023279986A1 (zh) * 2021-07-05 2023-01-12 贝达药业股份有限公司 六元芳基或杂芳基酰胺类化合物及其组合物和用途
MX2024001840A (es) 2021-08-09 2024-02-28 Janssen Pharmaceutica Nv Composiciones para usar en el tratamiento de neoplasias de celulas b.
CN113912511B (zh) * 2021-11-29 2024-02-13 广东广康生化科技股份有限公司 一种联苯肼酯中间体的合成方法
IL313925A (en) 2021-12-30 2024-08-01 Jiangsu Hansoh Pharmaceutical Group Co Ltd Inhibitor of tricyclic derivatives, method of preparation therefor and application
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
JP2025506410A (ja) * 2022-02-03 2025-03-11 シーフォーエックス・ディスカバリー・リミテッド Ｍａｌｔ１阻害剤としてのヘテロ環誘導体
TW202430031A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
TW202430514A (zh) 2022-09-30 2024-08-01 瑞士商先正達農作物保護股份公司 殺微生物之吡唑衍生物
JP2025539452A (ja) 2022-11-30 2025-12-05 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物テトラヒドロイソキノリン誘導体
WO2024125628A1 (zh) * 2022-12-16 2024-06-20 江苏恒瑞医药股份有限公司 一种Malt 1抑制剂的磷酸酯前药
CN121285553A (zh) * 2023-06-29 2026-01-06 上海翰森生物医药科技有限公司 一种三并环类衍生物抑制剂的晶型及其制备方法
WO2025002340A1 (zh) * 2023-06-29 2025-01-02 上海翰森生物医药科技有限公司 三并环类抑制剂与抗癌剂在制备抗肿瘤药物中的联合应用
WO2025069270A1 (ja) * 2023-09-27 2025-04-03 日本新薬株式会社 アザインドール化合物及び医薬
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor
WO2025114167A1 (en) 2023-11-28 2025-06-05 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025174889A1 (en) * 2024-02-13 2025-08-21 Board Of Regents, The University Of Texas System Malt1 and btk dual inhibitors
WO2025191053A1 (en) 2024-03-14 2025-09-18 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025210095A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Microbiocidal tetrahydroisoquinoline compounds
WO2025210096A1 (en) 2024-04-03 2025-10-09 Syngenta Crop Protection Ag Fungicidal compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
GB9925127D0 (en) 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US7223782B2 (en) 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
EP1622571A4 (en) * 2003-04-30 2012-05-02 Agensys Inc NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER
ATE482200T1 (de) * 2003-05-01 2010-10-15 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
JPWO2006085685A1 (ja) 2005-02-09 2008-06-26 武田薬品工業株式会社 ピラゾール化合物
CN100526430C (zh) 2005-10-19 2009-08-12 中国石油化工股份有限公司 一种生产清洁汽油的方法
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
RU2008141761A (ru) 2006-03-22 2010-04-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
JP2009542809A (ja) 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
EA200970841A1 (ru) 2007-03-09 2010-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтическое применение замещенных амидов
CN101366715A (zh) 2007-08-15 2009-02-18 上海医药工业研究院 一种雷帕霉素组合物及其制备方法
ATE553769T1 (de) 2007-11-21 2012-05-15 Vib Vzw Inhibitoren der malt1-proteolytischen aktivität und ihre verwendung
JP5536073B2 (ja) 2008-09-24 2014-07-02 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫を防除するためのピラゾール化合物
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
WO2011036885A1 (ja) 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
ES2539379T3 (es) 2010-06-22 2015-06-30 Basf Se Procedimiento de preparación de 4-hidroxipiridinas
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
TW201236685A (en) 2010-11-11 2012-09-16 Daiichi Sankyo Co Ltd New pyrazole amide derivatives
CN104507933B (zh) 2012-05-31 2017-10-31 霍夫曼-拉罗奇有限公司 氨基喹唑啉和吡啶并嘧啶衍生物
WO2014033447A2 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
MX2015005744A (es) 2012-11-09 2016-02-10 Univ Cornell Inhibidores de malti de molecula pequeña.
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
WO2014108337A1 (en) 2013-01-10 2014-07-17 Grünenthal GmbH Pyrazolyl-based carboxamides i as crac channel inhibitors
JP2015096499A (ja) * 2013-10-11 2015-05-21 田辺三菱製薬株式会社 医薬組成物
CR20160548A (es) 2014-05-28 2017-01-02 Novartis Ag Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
WO2015192081A1 (en) 2014-06-13 2015-12-17 Byrd, John C. Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016005994A2 (en) 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires
EP3177366A4 (en) 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
DK3191449T3 (da) 2014-09-10 2020-08-03 Glaxosmithkline Ip Dev Ltd Forbindelser som ret- (rearranged during transfection) hæmmere
JP6608933B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10835524B2 (en) 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
LT3371190T (lt) 2015-11-06 2022-08-10 Incyte Corporation Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
SG11201803480WA (en) * 2015-11-13 2018-05-30 Novartis Ag Novel pyrazolo pyrimidine derivatives
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
WO2017151786A1 (en) 2016-03-01 2017-09-08 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
KR20190033607A (ko) 2016-07-29 2019-03-29 루핀 리미티드 Malt1 저해제로서의 치환 티아졸로-피리딘 화합물
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
CA3046578A1 (en) 2016-12-21 2018-06-28 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
JOP20190148A1 (ar) 2016-12-21 2019-06-18 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية
JOP20190141A1 (ar) 2016-12-21 2019-06-12 Bayer Pharma AG أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي
CN110325548B (zh) 2016-12-21 2023-11-17 美莱奥生物制药第三有限公司 抗硬化蛋白抗体在治疗成骨不全症中的用途
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
JP7142022B2 (ja) 2017-03-08 2022-09-26 コーネル・ユニバーシティー Ｍａｌｔ１の阻害剤およびそれらの使用
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
WO2019133809A1 (en) 2017-12-28 2019-07-04 The General Hospital Corporation Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
WO2019161921A1 (de) 2018-02-23 2019-08-29 Industrieanlagen-Betriebsgesellschaft Mbh Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
US11040031B2 (en) 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
US10888550B2 (en) 2018-06-18 2021-01-12 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
BR112021016411A2 (pt) 2019-02-22 2021-10-13 Janssen Pharmaceutica N.V. Formulações farmacêuticas
CA3129623A1 (en) 2019-02-22 2020-08-27 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
CA3162140A1 (en) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Methods for assessing efficacy of malt1 inhibitors using an nf-kb translocation assay
WO2021099612A1 (en) 2019-11-22 2021-05-27 Janssen Pharmaceutica Nv Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
AU2021328320A1 (en) 2020-08-21 2023-05-04 Janssen Pharmaceutica Nv Amorphous form of a malt1 inhibitor and formulations thereof
CN115884773A (zh) 2020-08-21 2023-03-31 詹森药业有限公司 药物制剂
WO2022185097A1 (en) 2021-03-03 2022-09-09 Janssen Pharmaceutica Nv Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)
KR20230154232A (ko) 2021-03-03 2023-11-07 얀센 파마슈티카 엔브이 Malt1 억제제 및 btk 억제제를 사용하는 병용 치료

Also Published As

Publication number Publication date
CL2019001709A1 (es) 2019-10-04
AR110421A1 (es) 2019-03-27
TW201835067A (zh) 2018-10-01
TWI795381B (zh) 2023-03-11
AU2017382185C9 (en) 2022-08-04
MX392673B (es) 2025-03-24
BR112019012355A2 (pt) 2019-11-26
EP3558969A1 (en) 2019-10-30
UY37537A (es) 2018-06-29
EA201991503A1 (ru) 2019-11-29
UA127920C2 (uk) 2024-02-14
US12077521B2 (en) 2024-09-03
CO2019006622A2 (es) 2019-06-28
IL267343A (en) 2019-08-29
US20180170909A1 (en) 2018-06-21
JP7138641B2 (ja) 2022-09-16
AU2022201352A1 (en) 2022-03-24
US20220315557A1 (en) 2022-10-06
IL267343B2 (en) 2023-06-01
AU2017382185C1 (en) 2022-08-11
EP3558969B1 (en) 2024-09-18
CA3048027A1 (en) 2018-06-28
CN110214136A (zh) 2019-09-06
MX2022005827A (es) 2022-06-08
PE20191755A1 (es) 2019-12-12
EP3558969C0 (en) 2024-09-18
MA47125A (fr) 2021-04-28
KR20190093669A (ko) 2019-08-09
AU2017382185B2 (en) 2021-12-02
US10954214B2 (en) 2021-03-23
KR102583317B1 (ko) 2023-09-27
PH12019501212A1 (en) 2019-12-16
WO2018119036A1 (en) 2018-06-28
AU2017382185A1 (en) 2019-06-13
ES2992411T3 (es) 2024-12-12
JP2020514267A (ja) 2020-05-21
TN2019000192A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
MX2020004538A (es) Moduladores de la vía de estrés integrada.
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
JO3466B1 (ar) مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
PH12020552206A1 (en) Pyrazole derivatives as malt1 inhibitors
PH12020552207A1 (en) Pyrazole derivatives as malt1 inhibitors
EA201990400A1 (ru) Соединения и композиции и их применение
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MX382175B (es) Composiciones de profármaco de monometilfumarato
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
DOP2021000151A (es) Moduladores de la vía de estrés integrada
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam